DQA

Chieron has established a strong presence in specific therapeutic segments such as cardiovascular and central nervous system (CNS). The company aspires to maintain its market leadership in these areas by continuously adding new molecules and expanding its global footprint. VNAIs strategy includes global filings and approvals for all its products, enabling the company to engage with key customers worldwide. This approach has helped the company build a sustainable business model with a well-organized production and inventory planning system.

Chieron stands as a pioneer manufacturer of unique niche Active Pharmaceutical Ingredients (APIs), holding prestigious approvals, including six Certificates of Suitability (COS) Approval, USFDA, and Korean FDA Approvals. But our journey doesnt end here; we are tirelessly pursuing approvals from ANVISA and the Chinese cFDA for our key products.

Established in the year 2007, our mission has always been clear: Delivering Best Quality and Cost Leadership in the supply of Intermediates & APIs to customers globally while achieving the highest levels of customer satisfaction.

Our strategic focus on Backward Integration not only ensures cost competitiveness but also guarantees supply reliability and impeccable quality control. We proudly serve as a Contract Development and Manufacturing Organization (CDMO/CMO) partner to esteemed clients across Europe, Japan, and the Korean Region and expanding our presence Globally.

Innovation is at our core, with world-class Research and Analytics Laboratories facilitating new product development, alongside a Pilot plant conveniently located on-site. Our Compliance trails show the strength about our quality systems.